We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+16.22%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$593M
AUM Growth
+$248M
Cap. Flow
+$187M
Cap. Flow %
31.46%
Top 10 Hldgs %
30.55%
Holding
100
New
16
Increased
48
Reduced
17
Closed
11

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$13.1M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$12.8M
3
NKTR icon
Nektar Therapeutics
NKTR
+$10.4M
4
UHS icon
Universal Health Services
UHS
+$9.62M
5
AMGN icon
Amgen
AMGN
+$9.42M

Top Sells

Rank Stock Value
1
UTI icon
Universal Technical Institute
UTI
+$6.79M
2
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$5.83M
3
GILD icon
Gilead Sciences
GILD
+$4.79M
4
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$4.37M
5
CELG
Celgene Corp
CELG
+$3.7M

Sector Composition

Rank Sector Weight
1 Healthcare 83.68%
2 Financials 0.74%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
51
DELISTED
Clovis Oncology, Inc.
CLVS
$4.01M 0.68%
54,000
-31,398
-37% -$2.22M
ABMD
52
DELISTED
Abiomed Inc
ABMD
$3.94M 0.66%
55,000
-18,000
-25% -$977K
OCR
53
DELISTED
OMNICARE INC
OCR
$3.85M 0.65%
50,000
+25,000
+100% +$1.9M
KERX
54
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$3.78M 0.64%
297,000
+206,576
+228% +$2.66M
THOR
55
DELISTED
THORATEC CORPORATION
THOR
$3.64M 0.61%
87,000
-5,000
-5% -$191K
RIGL icon
56
Rigel Pharmaceuticals
RIGL
$750M
$3.57M 0.6%
+100,000
New +$2.74M
CNC icon
57
Centene
CNC
$32.5B
$3.39M 0.57%
96,000
-16,000
-14% -$481K
HOLX
58
DELISTED
Hologic
HOLX
$3.34M 0.56%
101,000
+7,000
+7% +$215K
MGNX icon
59
MacroGenics
MGNX
$257M
$3.33M 0.56%
106,000
+31,000
+41% +$1.05M
CLDX icon
60
Celldex Therapeutics
CLDX
$3.28B
$3.32M 0.56%
7,933
-3,734
-32% -$1.34M
ELGX
61
DELISTED
Endologix Inc
ELGX
$3.31M 0.56%
19,400
– –
PRGO icon
62
Perrigo
PRGO
$1.78B
$3.31M 0.56%
+20,000
New +$3.19M
STJ
63
DELISTED
St Jude Medical
STJ
$3.19M 0.54%
48,800
+8,800
+22% +$585K
ARIA
64
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$3.19M 0.54%
387,000
-10,000
-3% -$73.9K
ANTH
65
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$3.13M 0.53%
87,664
+37,664
+75% +$1.11M
TEVA icon
66
Teva Pharmaceuticals
TEVA
$41.2B
$3.12M 0.53%
+50,000
New +$2.91M
TSRO
67
DELISTED
TESARO, Inc.
TSRO
$3.04M 0.51%
52,999
-9,652
-15% -$455K
LGND icon
68
Ligand Pharmaceuticals
LGND
$6.36B
$3.01M 0.51%
62,517
– –
PODD icon
69
Insulet
PODD
$9.79B
$3M 0.51%
90,000
+38,000
+73% +$1.28M
CPHD
70
DELISTED
Cepheid Inc
CPHD
$2.96M 0.5%
52,000
– –
SYK icon
71
Stryker
SYK
$130B
$2.95M 0.5%
+32,000
New +$2.98M
ARRY
72
DELISTED
Array Biopharma Inc
ARRY
$2.95M 0.5%
400,000
-145,000
-27% -$1.03M
XNCR icon
73
Xencor
XNCR
$1.55B
$2.91M 0.49%
190,000
+140,000
+280% +$2.21M
OMCL icon
74
Omnicell
OMCL
$1.68B
$2.81M 0.47%
+80,000
New +$2.64M
ACHN
75
DELISTED
Achillion Pharmaceuticals
ACHN
$2.76M 0.47%
280,000
-88,000
-24% -$1.1M
1 2
3
4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2015 Portfolio in Review

As of Q1 2015, Rhenman & Partners Asset Management held 100 positions worth $593M, up 72% from $345M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $187M of net new capital in Q1 2015, opening 16 new positions and adding to 48 existing holdings. Its largest new stake was Universal Health Services: 87,000 shares worth $10.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 81% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Gilead Sciences, an estimated $4.79M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2015 buy was Universal Health Services: 87,000 shares worth $10.2M.
  • Rhenman & Partners Asset Management added most to Merck in Q1 2015, an estimated $13.1M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2015 reduction was Gilead Sciences, cutting an estimated $4.79M.
  • Rhenman & Partners Asset Management fully exited Universal Technical Institute in Q1 2015, selling an estimated $6.79M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $593M portfolio in Q1 2015.
  • Rhenman & Partners Asset Management opened 16 new positions and closed 11 in Q1 2015.
  • Rhenman & Partners Asset Management's portfolio value rose 72% quarter-over-quarter to $593M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2015, filed 13 May 2015.